SCNI

JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), has appointed Mr. Eilon Elmalem as Site Head of its Yavne CDMO facility, effective June 14, 2026. Mr. Elmalem has worked with Scinai over the past two years as an external consultant and has supported the Company's CDMO activities and operational development efforts. More recently, he has been involved in the transition and operational

EFFECT - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

424B3 - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

JERUSALEM, May 15, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), ("Scinai" or the "Company") a biopharmaceutical company focused on inflammation and immunology, today announced that members of its leadership team will lead a strategic roundtable discussion at the 7th Dermatology Drug Development Summit Europe, taking place next week in Amsterdam, the Netherlands. The roundtable discussion, titled "Oral Therapies and the Future of Biologics: How Oral Peptides and Small Molecules Are Reshaping the Immunology Landscape", will be led by Amir Reichman, Chief Executive Officer of Scinai Immunotherapeutics, together with Dr. Meital Portugal, Director of R&D Operations.The discu

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

F-3 - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

Financing led by institutional life sciences investor, with participation from new and existing investorsCapital expected to support expansion of CDMO platform and advancement of customer programsJERUSALEM, April 24, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics and the owner of Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), today announced that it has entered into a securities purchase agreement with an institutional life sciences investor, as well as with new and existing institutional and acc

JERUSALEM, April 6, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation and immunology therapeutics and operating a growing CDMO business, today announced the completion of a strategic corporate reorganization establishing a dedicated CDMO platform alongside a streamlined R&D organization. Building on its previously announced acquisition of Recipharm Israel Ltd. and related commercial collaboration with Recipharm, this reorganization represents a structural transformation of the Company's operating model, designed to enhance capital efficiency, improve operational focus and position each business

JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to combine therapeutic innovation with revenue-generating drug development and manufacturing services, today reported financial results for the year ended December 31, 2025. Corporate and Financial HighlightsCDMO revenues doubled year-over-year to $1.3 million, reflecting continued commercial traction and execution of development and manufacturing programsExpanded CDMO platform post year-end through the acquisition of Recipharm Israel and entry into a strategic commercial collaboration with Reciph

20-F - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, and the owner of Scinai Biopharma Services Ltd., a rapidly expanding contract development and manufacturing organization (CDMO) serving biotechnology and pharmaceutical companies, today announced its participation in BIO-Europe Spring® 2026, taking place March 23–25 in Lisbon, Portugal. This will be Scinai's first major international conference following its recent acquisition of Recipharm Israel and strategic collaboration with Recipharm, marking a significant expansion of its development and manufact

3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

JERUSALEM, March 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), today announced that it received a written notification from the Nasdaq Listing Qualifications Department on March 12, 2026 indicating that the Company is not in compliance with the Nasdaq Capital Market's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the American Depositary Shares ("ADSs") was below $1.00 per share for 30 consecutive business days. The notification has no immediate effect on the listing or trading of the ADSs on the Nasdaq Capital Market.In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has

JERUSALEM, March 2, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI);("Scinai" or the "Company"), today announced the execution of a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l., and the submission of a revised application under the European Funds for the Modern Economy (FENG) SMART Path program. The Company's revised application seeks €12 million in non-dilutive, non-repayable funding to support a €15 million integrated R&D program for PC111 a fully human monoclonal antibody targeting soluble Fas Ligand (sFasL) for the treatment of pemphigus vulgaris (PV) and Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN), representin